Highlights

  • Bubs Australia (ASX:BUB) shares closed at A$0.13, down 3.70% on 9 September 2026.
  • BUB secured permanent US FDA authorisation on 7 September for Bubs Goat, Bubs 365 Day Grass Fed and Bubs Essential infant formula.
  • FY26 Revenue increased 9.2% to A$111.9 million, led by 24% growth in US revenue.
  • Investors are likely to monitor US distribution growth, gross margins, working-capital requirements, inventory conversion and the commercial benefits of permanent regulatory access.

Bubs Australia Limited (ASX:BUB) shares finished Wednesday lower, closing at A$0.13, down 3.70% on 9 September 2026.

The broader Australian market ended only slightly weaker. The S&P/ASX 200 (ASX:XJO) closed at 8,911.40 points, down 0.11% on 9 September 2026, while the S&P/ASX 300 (ASX:XKO) closed at 8,842.30 points, down 0.12%.

Consumer Staples moved higher overall, with the S&P/ASX 200 Consumer Staples (ASX:XSJ) closing at 13,170.4 points, up 0.25% on 9 September 2026.

BUB therefore underperformed both the broader market and its sector benchmark during the session. However, the daily decline should not automatically be attributed to the company’s recent FDA announcement. A share-price move can reflect trading flows, valuation changes and investor positioning, while longer-term performance will depend on commercial execution, margins, cash generation and the ability to scale sales.

Infant Nutrition Platform

Bubs Australia is an infant nutrition company offering premium products including goat milk infant formula, grass-fed cow milk infant formula and other specialist nutrition products.

The company operates Manufacturing capabilities in Australia and sells across domestic and international markets including the United States, China and parts of Asia.

The US has become the most important growth market for BUB. Its products are now available in more than 10,000 stores across all 50 US states, with distribution spanning major retailers and online channels. The company’s FY26 presentation also showed expansion across Target, Walmart, Amazon, Kroger, Sam’s Club and other retail formats.

For investors, this gives BUB exposure to a large and highly regulated infant formula market, but it also means execution around Supply availability, compliance, retailer relationships, pricing and Marketing becomes increasingly important.

Permanent US FDA Approval

The most recent company update came on 7 September 2026, when BUB announced that it had secured permanent regulatory authorisation from the US Food and Drug Administration for three infant formula products: Bubs Goat, Bubs 365 Day Grass Fed and Bubs Essential.

The authorisation confirms that the company’s products, manufacturing systems and supporting scientific evidence satisfy US regulatory requirements for safety, nutritional adequacy and quality.

This is strategically significant because it moves BUB from temporary or transitional US market access onto a permanent regulatory footing.

The company said the approval positions it among a limited number of non-US manufacturers authorised to supply the US infant formula market. It also opens potential avenues for product innovation and participation in private-label infant nutrition, although any private-label expansion would still require further regulatory, technical and commercial milestones.

BUB also said the permanent approval provides a platform to strengthen retailer partnerships and expand its consumer reach.

FY26 Growth

The FDA development follows BUB’s FY26 results released on 27 August 2026.

Revenue increased 9.2% to A$111.9 million from A$102.5 million in FY25, landing within the company’s A$105 million to A$115 million guidance range. US revenue increased 24% to A$65.8 million and was the primary contributor to group growth.

Underlying EBITDA improved to A$5.3 million from A$1.2 million in FY25, while reported EBITDA was a loss of A$1.8 million.

The gap between reported and underlying Earnings reflected several temporary costs, including air freight, regulatory reset expenses and US tariff-related costs. Gross Profit was A$44.5 million, while the reported gross Margin declined to 39.8% from 47.8% in FY25.

BUB recorded a net loss after tax of A$4.6 million, compared with a A$5.5 million profit in FY25.

The results therefore showed continued sales expansion but also highlighted the financial impact of building inventory, navigating regulatory changes and supporting rapid US growth.

Inventory and Cash Flow

Working Capital remains an important consideration.

BUB increased inventory to A$36.3 million at the end of FY26 from A$20.1 million a year earlier. Management described this as a targeted restocking program designed to improve supply continuity and support future growth. The company said the inventory rebuild was complete at the end of the period.

Operating Cash Flow was negative A$15.1 million, largely reflecting the A$16.2 million inventory increase. Closing cash stood at A$9.4 million, while A$10 million had been drawn under bank facilities to support inventory and working-capital requirements.

For investors, the next test is whether higher inventory can now be converted into sales without requiring the same level of additional working-capital investment.

Cash conversion may therefore become increasingly important alongside revenue growth.

US Expansion and Investor Focus

The US remains central to the growth outlook.

BUB’s distribution expanded from about 4,000 stores to more than 10,000 stores during FY26. The company reported a 1% share of the total US infant formula market, an 8% share of the premium natural category and a 20% share of goat infant formula.

The permanent FDA authorisation removes a significant regulatory uncertainty and gives the company greater visibility over its ability to remain in the market.

However, investors will still need to assess commercial execution. Wider distribution does not automatically guarantee stronger profitability. Marketing expenditure, retailer economics, freight, tariffs and manufacturing costs all affect the earnings generated from additional sales.

China is another market to monitor. FY26 China revenue was A$21.4 million, broadly flat, while distribution through the online-to-offline channel expanded beyond 1,800 stores.

Australia generated A$18.3 million in revenue, down 7%, reflecting competitive conditions and earlier supply constraints. Management has been increasing marketing and retail activity as it seeks to rebuild momentum domestically.

Final Takeaway

Bubs Australia (ASX:BUB) shares closed at A$0.13, down 3.70% on 9 September 2026, while the S&P/ASX 200 Consumer Staples index gained 0.25%.

The more significant corporate development is the permanent US FDA authorisation secured on 7 September 2026 for three BUB infant formula products. The approval strengthens the company’s regulatory foundation in its largest growth market and creates additional commercial optionality.

FY26 revenue increased to A$111.9 million, led by 24% US growth, while underlying EBITDA improved to A$5.3 million. At the same time, lower reported margins, working-capital investment and negative Operating Cash Flow highlight the importance of converting scale into sustainable profitability.

For investors, the focus is likely to remain on US sales growth, retailer expansion, gross margins, inventory conversion, cash generation and whether permanent FDA access can translate into stronger long-term earnings.